|
| Case reports | Source of infection | Resistance mechanisms | Definitive treatment regimen | Outcome |
|
| United States case reports | | | | |
|
| Sherwood et al. [1] | Bacteremia + wound | nimE | Moxifloxacin 400 mg IV q24 h + linezolid 600 mg IV q12 h
Duration: 8 weeks | Survived |
|
| Kapalpila et al. [2] | Bacteremia + intra-abdominal fluid | No molecular investigation; resistant to MTZ1, imipenem, PTZ1, clindamycin, cefotetan, amp/sul1, moxifloxacin | Ertapenem 1 g IV q24 hr + Linezolid 600 mg IV q12 hr
Duration: 4 weeks | Survived |
|
| Non-United States case reports | | | | |
|
| Ank et al. [3] | Bacteremia | cfiA, nimE, ermF, tetQ | Moxifloxacin 400 mg IV q24 h + piperacillin-tazobactam 4.5 g IV q8 hr
Duration: 7 days | Survived |
|
| Urbán et al. [4] | Abdominal fluid | cfiA, nimA, erm, cepA, tetQ | Locally applied antibiotic therapy/wound care | Survived |
|
| Hartmeyer et al. [5] | Bacteremia + intra-abdominal fluid | cfiA, nimD, ermF, tetQ, tetX | Meropenem + metronidazole
Duration: 6 days, discontinuation due to death | Died |
|
| Katsandri et al. (2 case reports) [6] | Case 1: bacteremia from a colitis
Case 2: esophagojejunal anastomotic leak | cfiA | Case 1: metronidazole 500 mg IV q8 h + cefotaxime 2 g IV q8 h
Case 2: imipenem 500 mg IV q8 h | Case 1: died
Case 2: died |
|
| Wareham et al. [7] | Bacteremia from pancreatitis | cfiA, ermF, tetQ, efflux pump bmeB9/B15 | Linezolid 600 mg IV q12 h | Died |
|
| Rotimi et al. (3 case reports) [8] | Case 1: paracolic abscess
Case 2: surgical wound
Case 3: groin and scrotal abscess | No molecular investigation; resistant to MTZ | Case 1: imipenem 500 mg IV q8 h
Case 2: amoxicillin-clavulanate acid 600 mg PO q8 h
Case 3: meropenem 500 mg IV q8 h + cefepime + amikacin 500 mg IV q12 h | Case 1: survived
Case 2: survived
Case 3: died |
|
| Turner et al. [9] | Bacteremia from peritonitis and empyema | No molecular investigation; resistant to MTZ, imipenem, amoxicillin-clavulanate acid | Gentamicin and clindamycin | Survived |
|
